| scholarly article | Q13442814 |
| P50 | author | Mohammad Obaidul Hoque | Q58472169 |
| P2093 | author name string | Masahiro Shibata | |
| Kendall Ham | |||
| P2860 | cites work | YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response | Q24299975 |
| A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β-catenin signalling | Q24301588 | ||
| The Hippo pathway regulates Wnt/beta-catenin signaling | Q24307606 | ||
| MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer | Q24339513 | ||
| Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP | Q24594281 | ||
| The Hippo Signaling Pathway in Development and Cancer | Q24603986 | ||
| Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon | Q24682018 | ||
| Cellular composition of the tumor microenvironment | Q26824910 | ||
| The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment | Q27025661 | ||
| YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer | Q38978179 | ||
| An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer. | Q38982503 | ||
| Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies | Q39003420 | ||
| Regulatory T cells in cancer immunotherapy | Q39044365 | ||
| Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma | Q39062242 | ||
| Hippo vs. Crab: tissue-specific functions of the mammalian Hippo pathway | Q39081825 | ||
| YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKɛ-mediated phosphorylation. | Q39155971 | ||
| Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms | Q39158003 | ||
| YES-associated protein 1 promotes adenocarcinoma growth and metastasis through activation of the receptor tyrosine kinase Axl. | Q39214406 | ||
| YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29 | Q39246531 | ||
| Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. | Q39303842 | ||
| Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer | Q39447667 | ||
| Myeloid suppressor cells in cancer and autoimmunity | Q39448441 | ||
| miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. | Q39487411 | ||
| Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. | Q39586964 | ||
| Yes-associated protein (YAP) functions as a tumor suppressor in breast. | Q39962753 | ||
| The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation | Q40144929 | ||
| Drosophila warts--tumor suppressor and member of the myotonic dystrophy protein kinase family. | Q40475118 | ||
| RUNX3 is a novel negative regulator of oncogenic TEAD-YAP complex in gastric cancer | Q40545042 | ||
| YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling | Q40989829 | ||
| AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells. | Q41201253 | ||
| Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells | Q41260004 | ||
| Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. | Q41858851 | ||
| Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers | Q41871593 | ||
| Single tumor-initiating cells evade immune clearance by recruiting type II macrophages | Q41957741 | ||
| Key role of the positive feedback between PGE(2) and COX2 in the biology of myeloid-derived suppressor cells | Q42321651 | ||
| Aerobic glycolysis tunes YAP/TAZ transcriptional activity | Q35819661 | ||
| Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver | Q35832927 | ||
| Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation | Q35868895 | ||
| Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells | Q35874350 | ||
| Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients | Q35885488 | ||
| A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. | Q36027005 | ||
| YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression | Q36048228 | ||
| YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression | Q36086980 | ||
| COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells | Q36110362 | ||
| Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. | Q36134167 | ||
| YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. | Q36237330 | ||
| YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage | Q36414976 | ||
| Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression | Q36447669 | ||
| Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors | Q36455404 | ||
| Expression of tumoral FOXP3 in gastric adenocarcinoma is associated with favorable clinicopathological variables and related with Hippo pathway | Q36464531 | ||
| Yes associated protein is a poor prognostic factor in well-differentiated lung adenocarcinoma | Q36511765 | ||
| Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity | Q36710977 | ||
| YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells | Q36726132 | ||
| Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma | Q36881080 | ||
| Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells | Q36916380 | ||
| The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies | Q37058831 | ||
| PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment | Q37193568 | ||
| Transcriptional cofactor Mask2 is required for YAP-induced cell growth and migration in bladder cancer cell | Q37427970 | ||
| MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1 | Q37457780 | ||
| LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells. | Q37486949 | ||
| YAP promotes erlotinib resistance in human non-small cell lung cancer cells | Q37588390 | ||
| YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins | Q37623308 | ||
| VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex | Q37623587 | ||
| YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells | Q37706137 | ||
| Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. | Q37707464 | ||
| The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis | Q37820803 | ||
| Hippo signaling in Drosophila: recent advances and insights | Q37968995 | ||
| History of myeloid-derived suppressor cells | Q38141522 | ||
| Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma | Q38401343 | ||
| Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. | Q38415215 | ||
| YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2-EGFR Signaling Axis | Q38437859 | ||
| The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. | Q38542016 | ||
| YAP and TAZ Take Center Stage in Cancer | Q38606718 | ||
| Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy | Q38641116 | ||
| Hippo pathway and breast cancer stem cells | Q38685431 | ||
| Lung cancer stem cells: The root of resistance | Q38706873 | ||
| SPIN90 Depletion and Microtubule Acetylation Mediate Stromal Fibroblast Activation in Breast Cancer Progression | Q38708096 | ||
| The expanding role of immunotherapy. | Q38754012 | ||
| Sphingosine-1-phosphate induces COX-2 expression and PGE2 production in human granulosa cells through a S1P1/3-mediated YAP signaling. | Q38784875 | ||
| MiR-497 Suppresses YAP1 and Inhibits Tumor Growth in Non-Small Cell Lung Cancer | Q38840124 | ||
| Hsa-miR-132 inhibits proliferation of hepatic carcinoma cells by targeting YAP. | Q38861530 | ||
| Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway | Q38882539 | ||
| MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1. | Q38890422 | ||
| The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma | Q38890549 | ||
| YAP1 Regulates OCT4 Activity and SOX2 Expression to Facilitate Self-Renewal and Vascular Mimicry of Stem-Like Cells | Q38901912 | ||
| The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer | Q38903548 | ||
| Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression | Q38941672 | ||
| YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression | Q38966843 | ||
| YAP activation is an early event and a potential therapeutic target in liver cancer development. | Q38976729 | ||
| Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. | Q27310763 | ||
| Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance | Q27853210 | ||
| Immunity, Inflammation, and Cancer | Q27861048 | ||
| PD-1 and its ligands are important immune checkpoints in cancer | Q28069485 | ||
| Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment | Q28071935 | ||
| Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases | Q28131652 | ||
| YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells | Q28250934 | ||
| Cloning, expression, and transcriptional properties of the human enhancer factor TEF-1 | Q28282333 | ||
| The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation | Q28507317 | ||
| Role of YAP/TAZ in mechanotransduction | Q29615411 | ||
| EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer | Q29616360 | ||
| The Hippo signaling pathway in stem cell biology and cancer | Q30410176 | ||
| Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma | Q33594370 | ||
| Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma | Q33611696 | ||
| Blockade of Fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of Fas signaling-initiated cancer-related inflammation | Q33676412 | ||
| COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function | Q33678308 | ||
| YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes. | Q33757057 | ||
| Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer | Q33898459 | ||
| Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer | Q33943271 | ||
| KRAS and YAP1 converge to regulate EMT and tumor survival | Q33946244 | ||
| MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. | Q34103666 | ||
| Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma | Q34246014 | ||
| M1 and M2 Macrophages: Oracles of Health and Disease | Q34328890 | ||
| Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells. | Q34358867 | ||
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Q34522172 | ||
| COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells | Q34784887 | ||
| Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder | Q34840601 | ||
| The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation | Q34979150 | ||
| Increased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma | Q35005633 | ||
| Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response | Q35100037 | ||
| Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma. | Q35127831 | ||
| Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. | Q35553327 | ||
| R331W Missense Mutation of Oncogene YAP1 Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability | Q35657635 | ||
| The Hippo-YAP pathway: new connections between regulation of organ size and cancer | Q35811415 | ||
| Metaplastic carcinoma show different expression pattern of YAP compared to triple-negative breast cancer. | Q42467629 | ||
| Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients | Q42789703 | ||
| miR-375 inhibits proliferation of mouse pancreatic progenitor cells by targeting YAP1. | Q42809008 | ||
| Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells. | Q43001771 | ||
| Generation of myeloid-derived suppressor cells using prostaglandin E2. | Q43110927 | ||
| Differential expression of Yes-associated protein and phosphorylated Yes-associated protein is correlated with expression of Ki-67 and phospho-ERK in colorectal adenocarcinoma | Q44253428 | ||
| The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation | Q46192247 | ||
| PRKCI promotes immune suppression in ovarian cancer | Q47154650 | ||
| Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma | Q47864262 | ||
| Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer | Q48370038 | ||
| YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells | Q48588772 | ||
| YAP regulates PD-L1 expression in human NSCLC cells | Q49569691 | ||
| YAP-1 Promotes Tregs Differentiation in Hepatocellular Carcinoma by Enhancing TGFBR2 Transcription. | Q50672880 | ||
| Nuclear accumulation of Yes-Associated Protein (YAP) maintains the survival of doxorubicin-induced senescent cells by promoting survivin expression. | Q50872491 | ||
| Loss of MiR-424-3p, not miR-424-5p, confers chemoresistance through targeting YAP1 in non-small cell lung cancer. | Q51474565 | ||
| Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts. | Q52353619 | ||
| Metabolic control of YAP and TAZ by the mevalonate pathway. | Q52768568 | ||
| Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance. | Q53730688 | ||
| The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. | Q54336219 | ||
| Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer | Q83169055 | ||
| Expression of Yes-associated protein in non-small cell lung cancer and its relationship with clinical pathological factors | Q85465848 | ||
| RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway | Q87063270 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunosuppression | Q1455316 |
| P304 | page(s) | 2133-2144 | |
| P577 | publication date | 2018-04-26 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy. | |
| P478 | volume | 143 |
| Q92812554 | Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for Bladder Cancer |
| Q92155650 | Jiedu Sangen Decoction Inhibits the Invasion and Metastasis of Colorectal Cancer Cells by Regulating EMT through the Hippo Signaling Pathway |
| Q64238500 | Prognostic significance of nuclear Yes-associated protein 1 in patients with nonsmall cell lung cancer: A systematic review and meta-analysis |
| Q92060890 | RHPCG: a database of the Regulation of the Hippo Pathway in Cancer Genome |
| Q64885776 | Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer. |
| Q60908274 | The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer |
| Q59792731 | YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer |
| Q92617742 | Yes-associated protein 1 promotes bladder cancer invasion by regulating epithelial-mesenchymal transition |
| Q58796939 | miR‑590‑5p inhibits tumor growth in malignant melanoma by suppressing YAP1 expression |
Search more.